Urolog. pro Praxi, 2010; 11(5): 241-246

Comparison of efficacy and side effects of anticholinergic drugs in treating OAB

MUDr.Pavel Verner
Urocentrum, Praha

The article provides an overview of the efficacy, side effects and possible drug interactions and discusses additional aspects of pharmacotherapy

for overactive bladder with anticholinergic drugs: oxybutynin, propiverine, trospium, and drugs of second choice: tolterodine,

darifenacin, solifenacin and fesoterodine.

solifenacin, tolterodine, trospium.

Keywords: overactive bladder, hyperactive detrusor, anticholinergics, antimuscarinics, darifenacin, fesoterodine, oxybutynin, propiverine,

Published: October 22, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Verner P. Comparison of efficacy and side effects of anticholinergic drugs in treating OAB. Urol. praxi. 2010;11(5):241-246.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Skoupá J. Hyperaktivní měchýře: Nákladová efektivita oxybutininu IR a solifenacinu. Urolog. pro Praxi 2008; 9(2): 61-63.
    2. Poršová M. Propiverin a účinná léčba příznaků hyperaktivního močového měchýře u dětí a dospělých. Urolog. pro Praxi 2007; 5-6: 233-235.
    3. Poršová M, Kolombo I, Porš J, et al. Urgentní mikce a inkontinence a možnosti jejich farmakologické léčby. Urolog. pro Praxi 2008; (9)6: 302-306.
    4. Zachoval R. Fesoterodin, nové anticholinergikum pro léčbu hyperaktivního močového měchýře. Urolog. pro Praxi 2008; 9(6)6: 316-322.
    5. Krhut J. Hyperaktivní močový měchýř. Maxdorf-Jessenius 2007; 72-83.
    6. Krhut J, Havránek O. Léčba hyperaktivního měchýře u žen. Urol listy 2009; 7(4): 50-54.
    7. Současné možnosti léčby hyperaktivního měchýře. ZN Lék Listy 2010; 6: 18-23.
    8. Ellsworth PI, Brunton WEA, Wein AJ, et al. Progress in practice: Special Consideration in the management of overactive bladder, Brown Alpert Medical School, Urology University CMCE Newsletter, September 2009; 2: 1-9.
    9. Chapple ChR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of overactive bladder. Urology 2002; 60(suppl. 5A): 82-89. Go to original source... Go to PubMed...
    10. Mašata J. Anticholinergní látky v léčbě hyperaktivního močového měchýře. Remedia 2007; 1
    11. Chapple ChR, Khullar V, Gabriel Z. The effect of antimuscarinic treatments in overactive bladder: An uptade of a systematic review and Meta-analysis. Eur Urol. 2008; 54: 543-562. Go to original source... Go to PubMed...
    12. Lam S, Hilas O. Pharmacologic management of overactive bladder - review. Clin Interventions in Aging, 2007; 2(3): 337-345.
    13. Novara G, Galfano A, Secco S. A systematic Review a metaanalysis of randomized Controlled Trials with Antimuscarinic Drugs for overactive bladdder. Eur Urol 2008; 54: 740-764. Go to original source... Go to PubMed...
    14. Verner P. Darifenacin (profily léčiv). Farmakoterapie 2006; 5: 483-487.
    15. Verner P. Tolterodin (profily léčiv). Farmakoterapie 2005; 5: 464-469.
    16. Matoušková M. Solifenacin Remedia, 2009; 19: 170-175.
    17. Topinková E. Úskalí farmakoterapie urgentní inkontinence a hyperaktivního močového měchýře. Lék listy 2009; 12: 21-24.
    18. Drug Information on line: www.drugs.com.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.